Aurobindo Pharma Limited

Who owns Aurobindo Pharma?
Aurobindo Pharma is a publicly traded company listed on India's NSE and BSE. The Reddy founding family and related entities hold the largest shareholding bloc, with the remainder owned by institutional and public investors.

Is Aurobindo Pharma publicly traded?
Yes. It trades on the National Stock Exchange of India under the symbol AUROPHARMA and on the Bombay Stock Exchange under code 524804.

When was Aurobindo Pharma founded?
P. V. Ramaprasad Reddy and K. Nityananda Reddy founded the company in 1986 in Hyderabad, India, initially manufacturing semi-synthetic penicillins.

What does Aurobindo Pharma make?
Generic prescription medicines across most therapeutic categories, active pharmaceutical ingredients, and branded oncology injectables through its Acrotech Biopharma subsidiary, including Fusilev, Folotyn, Beleodaq, and Evomela.

What is Aurobindo Pharma's market position?
It is the largest generic drug supplier to the United States by prescription volume and one of the world's top-tier generics companies, with FY2025 revenue of INR 31,724 crore (about $3.7 billion) and sales in more than 150 countries.

Who makes Fusilev?
Fusilev (levoleucovorin) is marketed in the US by Acrotech Biopharma LLC, a wholly owned subsidiary of Aurobindo Pharma, which acquired it from Spectrum Pharmaceuticals in March 2019 as part of a seven-product oncology portfolio purchase.

P. V. Ramaprasad Reddy and K. Nityananda Reddy founded Aurobindo Pharma in 1986 in Hyderabad, beginning with a single unit manufacturing semi-synthetic penicillins. At the time, India's pharmaceutical industry was dominated by multinational subsidiaries and a handful of domestic companies such as Ranbaxy and Dr. Reddy's; Aurobindo entered as a scrappy domestic player focused on antibiotics.

The company went public on Indian exchanges in 1992 and spent the 1990s expanding capacity and product range, building API plants and formulation facilities. Its strategy of backward integration, making its own active ingredients, gave it cost advantages and supply security that pure formulators lacked.

International expansion defined the 2000s. Aurobindo entered the US generics market and grew rapidly through FDA approvals, becoming a top supplier in high-volume antibiotic and cardiovascular categories. Acquisitions followed: the company bought businesses in Europe, and in 2014 acquired the US commercial operations of Actavis's generics arm in a deal that expanded its American footprint, alongside other bolt-on purchases in South Africa and elsewhere.

A difficult period arrived in the late 2010s. FDA warning letters and import alerts hit several Aurobindo facilities over manufacturing quality concerns, part of an industry-wide crackdown on Indian generic plants, and the company spent years on remediation. In 2019, its US subsidiary Acrotech Biopharma acquired a portfolio of seven marketed oncology injectables from Spectrum Pharmaceuticals for $158.8 million upfront plus milestones, including Fusilev, Folotyn, Zevalin, Marqibo, Beleodaq, Evomela, and Khapzory, creating a branded specialty business inside the generic giant.

The 2020s brought recovery and diversification. Facilities cleared FDA reinspections, the company pushed into biosimilars and peptides, and it committed to a large vaccine manufacturing plant. FY2025 produced record results, with US formulations revenue growing 13.5% in the final quarter and the company holding its position as the top US generics supplier by prescription volume.

Aurobindo publishes an annual Business Responsibility and Sustainability Report filed with Indian regulators under SEBI requirements, covering environmental performance, occupational safety, waste management, and community programs run through its foundation. Key stated commitments include water management, renewable energy adoption across manufacturing sites, and antibiotic discharge controls relevant to its API production.

The company's ESG profile is shaped by the generic industry's core tension: it delivers enormous public health value by making essential medicines affordable, while facing periodic regulatory findings on manufacturing quality and pharmaceutical pollution, issues it addresses through remediation and compliance investment.

Aurobindo has faced significant FDA regulatory action over manufacturing quality. In the late 2010s and early 2020s, multiple facilities received warning letters, import alerts, and Form 483 observations covering data integrity and sterile manufacturing practices, temporarily restricting US shipments from affected plants. The company invested heavily in remediation, and the affected facilities progressively cleared reinspections.

The company was also among the generic manufacturers named in the sprawling US price-fixing litigation brought by state attorneys general alleging collusion on generic drug prices, charges the industry has contested and partially settled. Like other large Indian generics producers, Aurobindo faces ongoing scrutiny over effluent discharge and antimicrobial resistance linked to antibiotic API manufacturing.